Atlas Trials

Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer

Clinical trial NCT06639672 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06639672
Sponsor
Lei Liu
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HR+HER2- Breast Cancer
Start date
2024-11-01
Primary completion
2026-05-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.